Favorable outcome of severe acute hepatitis B in a patient treated with antithrombin III and antiviral therapy

Clinical Infectious Diseases

Volumn 49, Issue 3, 2009, Pages 481-

  Chalupa, Pavel ^a   Holub, Michal ^a  

^a UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTITHROMBIN III; ANTITHROMBIN III CONCENTRATE; BILIRUBIN; FRESH FROZEN PLASMA; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; LOW MOLECULAR WEIGHT HEPARIN; VITAMIN K GROUP;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ANTIVIRAL THERAPY; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TEST; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE COURSE; DISEASE SEVERITY; GENERAL CONDITION IMPROVEMENT; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HUMAN; IMMUNE RESPONSE; LETTER; LIVER FAILURE; MALE; OUTCOME ASSESSMENT; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROTHROMBIN TIME; TREATMENT RESPONSE;

ANTITHROMBIN III; ANTIVIRAL AGENTS; HEPATITIS B; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POINT MUTATION; TREATMENT OUTCOME;

EID: 67651119694     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600822     Document Type: Letter

References (3)

1. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 2004; 24:547-51.
2. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B: a multicenter experience. J Viral Hepat 2006; 13:256-63.
3. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001;286:1869-78.